To include your compound in the COVID-19 Resource Center, submit it here.
Data from 165 clinically evaluable patients in a double-blind, U.S. Phase II trial showed that twice-daily 100 and 150 mg IV BC-3781 produced
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury